Screening of HIV-Infected Patients with IGRAs for LTBI. Background. Tuberculosis is the most prevalent in the world.

Similar documents
Didactic Series. Latent TB Infection in HIV Infection

Peggy Leslie-Smith, RN

Interpretation of TST & IGRA results. Objectives

Didactic Series. Latent TB Infection in HIV Infection

Identifying TB co-infection : new approaches?

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

TB in Corrections Phoenix, Arizona

Testing for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle

TB Intensive Tyler, Texas December 2-4, 2008

TB Update: March 2012

Using Interferon Gamma Release Assays for Diagnosis of TB Infection

Approaches to LTBI Diagnosis

Making the Diagnosis of Tuberculosis

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

Conflict of Interest Disclosures:

Investigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay

Case Management of the TB/HIV Infected Patient

Technical Bulletin No. 172

TB Prevention Who and How to Screen

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

Diagnosis Latent Tuberculosis. Disclosures. Case

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Diagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

TB Intensive Houston, Texas October 15-17, 2013

TB Intensive San Antonio, Texas November 11 14, 2014

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

Tuberculosis: Where Are We Now?

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:

LATENT TUBERCULOSIS. Robert F. Tyree, MD

Diagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011

Northwestern Polytechnic University

QuantiFERON-TB Gold Plus

Detecting latent tuberculosis using interferon gamma release assays (IGRA)

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Self-Study Modules on Tuberculosis

Diagnosis and Medical Management of Latent TB Infection

Tuberculosis Tools: A Clinical Update

Latent TB Infection (LTBI)

Revised Technical Instructions for Civil Surgeons. October 9, 2018

Director, University Health Services. Medical Director

Effect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Testing & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat?

Tuberculosis Update. Topics to be Addressed

New Standards for an Old Disease:

Adachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal

Diagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Diagnosis & Management of Latent TB Infection

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

Osaka City is the third largest city (population

Latent TB, TB and the Role of the Health Department

ESCMID Online Lecture Library. by author

No, not these...or these.

QFT. 457 QuantiFERON -TB 2nd Generation QFT m 2 キーワーズ QFT QFT QFT QFT BCG. Kekkaku Vol. 85, No. 6: 547_552, 2010

Audit of management of TB in HIV co-infected patients: survey of clinic arrangements

ATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS

Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -

TB in the Patient with HIV

Guidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors

The Most Widely Misunderstood Test of All

Factors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis

Contracts Carla Chee, MHS May 8, 2012

TB in Corrections Phoenix, Arizona

Thorax Online First, published on December 8, 2009 as /thx

Diagnosis and Medical Management of LTBI

Student Health Requirements Master of Arts, Biomedical Sciences Program

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

The Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

International Journal of Innovative Research in Medical Science (IJIRMS)

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Contact Investigation and Prevention in the USA

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)

Tuberculosis Intensive

Primary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service

IGRAs for Diagnosis of Tuberculosis: 2010 Update

TB Laboratory for Nurses

Diagnosis of tuberculosis

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

Literature Overview. Health Economics. Experience with QuantiFERON -TB Gold. Cellestis Clinical Guide series

Journal of Infectious Diseases Advance Access published August 2, 2013

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

Communicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts

QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients

These recommendations will remain in effect until the national shortage of PPD solution has abated.

Transcription:

Screening of HIV-Infected Patients with IGRAs for LTBI Kentaro Sakashita, Akira Fujita, Shuji Hatakeyma Stay strong, Japan! Tokyo Metropolitan Tama Medical Center Department of Pulmonary Medicine Background Tuberculosis is the most prevalent opportunistic infection in HIV-infected patients in the world. It is believed that IGRAs has low sensitivity among HIV-infected patients due to their immune-suppressed status. This study aims to assess whether IGRAs can be used as a screening tool to detect LTBI in asymptomatic, HIV-infected patients in Japan.

TB Statistics in Japan in 2010 Newly notified TB patients 23,361361 cases in the whole country Rate 18.2* 3,045 cases in Tokyo Rate 23.1* Sputum smear positive pulmonary TB 9,019 cases in the whole country Rate 7.1* 1,099 cases in Tokyo Rate 8.3* *per 100,000 Moderate incidence country cases 1800 1600 1400 1200 1000 800 600 400 200 0 Newly Notified HIV Infection in Japan 1,544 new cases in 2010 400 Cumulative HIV cases 18,447 AIDS prevention Information Network in Japan, http://api-net.jfap.or.jp/status/index.html

Comparison of TB Notification Rates and HIV Prevalence in 2009 Japan Tokyo South east Asia U.S. 1 (2008) Newly notified TB* 19 25 118 4.1 HIV prevalence* 15 36 300 469 *per 100,000 Reference -AIDS prevention Information Network in Japan -WHO Global TB Control Report 2010 -UNAIDS REPORT ON THE GLOBAL AIDS EPIDEMIC 2010 1 CDC. HIV Surveillance --- United States, 1981--2008. MMWR 2011 60(21); 689-693. HIV/TB Co-infection in Japan, 2009 (Only cases reported about HIV status to public health center) Active tuberculosis Pulmonary TB 27 Sputum smear positive 15 Other bacillary positive 11 Bacillary negative 1 Extra-pulmonary TB 25 Total 52 Cumulative HIV cases in 2009 16,903 cases Estimated active TB among HIV-infected patients roughly 0.3% (307 per 100,000) Tuberculosis Annual Report 2009, Series 7. Condition of TB (2), Tuberculosis Surveillance Center, RIT, JATA

Objective To evaluate the utility of QuantiFERON -TB Gold In-Tube (QFT-GIT) as a screening tool to detect LTBI in HIVinfected patients in Japan. Subjects 44 HIV-infected patients Setting: Two HIV hub hospitals in Tokyo -Tokyo Metropolitan Tama Medical Center -Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital. 34 cases in outpatient clinic 10 cases on admission From January 2011 to November 2011 All patients are Japanese living in Tokyo. Exclusions -Active TB -Recent TB exposure -Past TB history -Past LTBI treatment

Methods We conformed to the product guideline of QFT- GIT approved by the Ministry of Health, Labor and Welfare, Japan. Whole blood (1ml) into each of three blood collection tubes: -A negative (Nil) control tube -A tube containing TB-specific test antigens (ESAT-6, CFP-10 and TB7.7) -A positive (Mitogen) control tube Incubated at 37 for 16 to 24 hours. Interferon-gamma concentration in the plasma is determined using a sensitive ELISA. Methods - Interpretation Criteria for QFT-GIT Interpretation Positive Doubtful positive* Negative TB Specific Antigen Response (IU/mL) 0.35 (and 25% of Nil) Nil Control (IU/mL) Mitogen Control (IU/mL) 0.35 8.0 any 0.1 and <0.35 0.5 < 0.35 (or < 25% of Nil) 8.0 0.5 < 0.35 8.0 < 0.5 Indeterminate (or < 25% of Nil) any > 8.0 any *Definition of doubtful positive in Japan

Basic Characteristics Total n=44 Age 47 ± 13 yrs [28-80] Age 70 yrs 4 (9.0%) Sex Male 37 (84.0%) Female 7 (16.0%) CD4 cell count 398 ± 275 /mm 3 [6-1180] CD4 cell count <200 /mm 3 7 (16.0%) Diabetes mellitus 2 (4.5%) Chronic kidney disease 0 Immune-suppressive therapy 0 Number of Patients by CD4 Cell Count (n) (n=44) 12 10 8 6 4 2 0 (/mm 3 )

Dot Plot of Individual Response to Mitogen for HIV-infected Patients (n=44) IU/ml > 10 8 6 4 2 0 0 200 400 600 800 1000 1200 CD4 cell count (/mm 3 ) Dot Plot of TB-Ag-Nil for HIV-infected Patients (n=42, excluding two indeterminate cases) IU/ml 0.6 0.56 0.5 0.4 0.35 0.3 0.2 01 0.1 0.24 0.11 0.34 04 0.4 Doubtful positive 0-0.1-0.2 CD4 cell count (/mm 3 )

Result of QFT Interpretation QFT n Positive 2 (4.5%) Negative 37 (84%) Doubtful positive* 3 (6.8%) Indeterminate 2 (4.5%) Total 44 *Definition of doubtful positive in Japan 0.1 TB-Ag-Nil<0.35 IU/mL and Mitogen-Nil>0.5 IU/mL Result of QFT Interpretation in Patients with CD4 Cell Count below 200 or over 200/mm 3 CD4 <200/mm 3 200/mm 3 Total Interpretation Positive 0 2 2 Negative 5 32 37 Doubtful positive 0 3 3 Indeterminate 2 0 2 Total 7 37 44

Profiles of QFT Positive Cases Case 1 44 yrs M Case 2 56 yrs M TB-Ag-Nil (IU/ml) 0.56 0.4 Mitogen-Nil (IU/ml) >10 >10 CD4 (/mm 3 ) 1,102 359 ART TDF/FTC +EFV AZT/3TC +LPV/RTV None Symptom Sputum smear Negative AFB culture Negative Chest X-ray No abnormality Treatment INH 300mg 9 months TDF=Tenofovir, FTC=Emtircitabine, EFV=Efavirenz, RAL=Raltegravir Profiles of QFT Doubtful Positive Cases Case 3 59 yrs M Case 4 49 yrs M Case 5 36 yrs M TB-Ag-Nil (IU/ml) 0.34 0.1 0.24 Mitogen-Nil (IU/ml) >10 >10 >10 CD4 (/mm 3 ) 624 580 216 ART Symptom Sputum smear AFB culture Chest X-ray Treatment TDF/FTC +EFV TDF/FTC +EFV None Negative Negative No abnormality Watchful observation TDF+EFV +RAL

1 Harada N. et al. J Infect 2008;56:348-353 This study is the only one published study which are inspected about the specificity of QFT-GIT in healthy population in Japan. Result of QFT-GIT Interpretation in Low Risk Adults QFT n Positive 2 (1.1%) 1%) Negative 152 (90%) Doubtful positive 8 (4.7%) Indeterminate 6 (3.5%) Total 168 We made this figure according to data of the original paper. 1 Harada N. et al. J Infect 2008;56:348-353

Summary Our study showed that the positive rate for QFT (QFT-GIT) among HIV-infected patients was 4.6%. It seems to be higher than that of the healthy population, which was shown to be 1.1% in the prior study in Japan. 1 1 Harada N. et al. J Infect 2008;56:348-353 QFT positive cases have been treated with INH. Doubtful positive cases are kept under watchful observation. Discussion

Our Situation TB incidence in Japan is still high, compared with that in other developed countries. In Japan, positive predictive value for IGRAs is expected to be reliable, especially in high risk groups including HIV-infected persons. No official recommendation for the treatment of LTBI in HIV-infected persons has been issued in Japan. QFT in HIV-infected Patients Our limited data found that QFT(QFT-GIT) might be useful to detect LTBI among asymptomatic, HIV infected patients in Tokyo. However, the usefulness was shown to be limited in low CD4 cell counts cases. 1 Fujita et al. showed that the frequency of an indeterminate QFT-G test was significantly higher in those with a CD4 cell count less than 50/mm 3. 2 1 Horsburght CR et al. N Engl J Med 2011;364:1441-8. 2 Fujita A, et al. Clin Dev Immunol.vol. 2011, pii:325295, 1-6,2010

Limitations of this Study The number of subjects was small. We only did single test in each patient We had no control group (just compared with other studies) A gold standard for determining TB infection is lacking QFT-positive result might be false-positive depending on the TB prevalence or the degree of TB risks. Further Investigation The adjustment of the cut off value in HIV- infected patients with a low CD4 cell count might be needed. Indication of LTBI treatment for doubtful positive cases with HIV-infection could be considered. We are likely to consider the timing of retest of IGRAs in indeterminate cases after immune-status recovery.

Conclusion In countries with moderate tuberculosis incidence, screening of HIV-infected patients with IGRAs(QFT-GIT) for LTBI may be beneficial. i Acknowledgment Atsushi Ajisawa, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital